CARBAMAZEPINE-INDUCED SYSTEMIC LUPUS ERYTHEMATOSUS-LIKE DISEASE

被引：15

作者：

KANNO, T

MIYATA, M

KAZUTA, Y

SATO, Y

NISHIMAKI, T

KASUKAWA, R

机构：

[1] Department of Internal Medicine II, Fukushima Medical College, Fukushima

来源：

INTERNAL MEDICINE | 1992年 / 31卷 / 11期

关键词：

DRUG-INDUCED SLE; ANTICONVULSANT;

D O I：

10.2169/internalmedicine.31.1303

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

A 14-year-old female developed systemic lupus erythematosus (SLE)-like symptoms, rash, fever, leukopenia and positive anti-nuclear antibody (ANA) two weeks after administration of carbamazepine (CBZ; Tegretol(R)) used against benign Rolandic epilepsy. Clinical symptoms and leukopenia normalized after discontinuation of CBZ and administration of prednisolone at 40 mg. The cases of CBZ-induced SLE reported in the literature were reviewed.

引用

页码：1303 / 1305

页数：3

共 13 条

[1]

Alarcon-Segovia D., Fishbein E., Reyes P.A., Et al., Antinuelear antibodies in patients on anticonvulsant therapy, Clin Exp Immunol, 12, (1972)

[2]

De Giorgio C.M., Rabinowicz A.L., Olivas R.D., Carbamazepine-induced antinuelear antibodies and systemic lupus erythematosus-like symdrome, Epilesia, 32, (1991)

[3]

Simpson J.R., Collagen disease due to carbamazepine, Br Med J, 2, (1966)

[4]

Alballa S., Fritzler M., Davis P., A case of induced lupus due to carbamazepine, J Rheumatol, 14, (1987)

[5]

Livingston S., Sakata Y., Pauli L.L., Carbamazepine in epilepsy, JAMA, 200, (1967)

[6]

Takigawa N., Kanoh T., Imamura S., Et al., IgA deficiency and systemic lupus erythematosus, Arch Dermatol, 112, (1976)

[7]

Kolstee H., A patient with systemic lupus erythematosus brought about by the use of carbamazepine (Tegretol), Ned Tijdschr Geneeskd, 127, (1983)

[8]

Bateman D.E., Carbamazepine induced SLE-Case report, Br Med J, 291, (1985)

[9]

Ken H., Terasawa S., Kondoh N., Et al., A case of carbamazepine-induced SLE-like syndrome, Tôkai Ryumachi, 18, (1987)

[10]

Drory V.E., Yust I., Korczyn A.D., Carbamazepine-induced systemic lupus erythematosus, Clin Neuropharma, 12, (1989)

← 1 2 →